Health & Medicine

STAT+: Eli Lilly's 'triple-G' drug leads to significant blood sugar, weight reductions in diabetes trial

24 sec read16 views0 listens

Eli Lilly's investigational drug retatrutide showed significant reductions in blood sugar and weight loss in diabetes patients, outperforming placebo and rivaling Lilly’s Mounjaro. The notable weight loss of 15.3% at the highest dose could mark a substantial advancement for diabetes treatment, offering hope for more effective management of both blood sugar and obesity.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Biotech & PharmaAug 2024 sec read

Is Targeted Protein Degradation the "Break" Neurology Needs?

Targeted protein degradation using PROTACs is showing promise in treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, particularly through the targeting of LRRK2 proteins. This development matters because it offers a more precise app...

Ali Nemati

Tech & GadgetsAug 1922 sec read

Kodeon acquires mental wellness app Breethe in largest acquisition to date

Toronto-based Kodeon has acquired Montréal’s mental wellness platform Breethe, marking its largest acquisition and expanding its portfolio of mobile life-improvement apps. This move is significant for developers as it highlights the growing importanc...

Ali Nemati

Biotech & PharmaJul 2028 sec read

Protein Protects Against Tau Tangles, Synaptic Loss in Mouse Model of Tauopathy

Scientists at Sanford Burnham Prebys have discovered that the SORLA protein protects against tau tangles and synaptic loss in a mouse model of tauopathy, suggesting potential new treatments for Alzheimer’s disease. This finding is significant as it i...

Ali Nemati